Determinants of Human Immunodeficiency Virus Type 1 Resistance to gp41-Derived Inhibitory Peptides

L Rimsky, Diane C. Shugars, Thomas J. Matthews

Journal of Virology

Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial

Jean‐Michel Molina, Pedro Cahn, Beatriz Grinsztejn, +9

The Lancet

Treatment And PreventionAntiviral Drug DevelopmentClinical TrialsRilpivirine Versus EfavirenzAntiviral Therapy +6

Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial

Calvin Cohen, Jaime Andrade‐Villanueva, Bonaventura Clotet, +9

The Lancet

Treatment And PreventionMedicineHuman RetrovirusClinical TrialsRilpivirine Versus Efavirenz +7

TMC278, a Next-Generation Nonnucleoside Reverse Transcriptase Inhibitor (NNRTI), Active against Wild-Type and NNRTI-Resistant HIV-1

Hilde Azijn, Ilse Tirry, Johan Vingerhoets, +7

Antimicrobial Agents and Chemotherapy

Hiv-1 Group MMedicineHuman RetrovirusImmunologyAntiviral Therapy +13

Cloning and expression of a cDNA for human thioredoxin.

E Wollman, L d'Auriol, L Rimsky, +7

Journal of Biological Chemistry

Protein ExpressionCellular EnzymologyBiochemistryNatural SciencesMedicine +11

Functional replacement of the HIV-1 rev protein by the HTLV-1 rex protein

L Rimsky, Joachim Hauber, Mitchell Dukovich, +4

Nature

Viral ReplicationMolecular VirologyMedicineNatural SciencesHuman Retrovirus +10

Comparative analysis of the HTLV-I Rex and HIV-1 Rev trans-regulatory proteins and their RNA response elements.

S M Hanly, L Rimsky, Michael H. Malim, +7

Genes & Development

Viral ReplicationGeneticsImmunologyMolecular BiologyHtlv-i Rex +18

Genotypic and Phenotypic Characterization of HIV-1 Isolates Obtained From Patients on Rilpivirine Therapy Experiencing Virologic Failure in the Phase 3 ECHO and THRIVE Studies

L Rimsky, Johan Vingerhoets, Veerle Van Eygen, +5

JAIDS Journal of Acquired Immune Deficiency Syndromes

Rilpivirine VfsRilpivirine VfHuman RetrovirusImmunologyAntiviral Therapy +10

Efficacy and Safety of Rilpivirine (TMC278) Versus Efavirenz at 48 Weeks in Treatment-Naive HIV-1–Infected Patients

Calvin Cohen, Jean‐Michel Molina, Pedro Cahn, +13

JAIDS Journal of Acquired Immune Deficiency Syndromes

PharmacotherapyAntiviral DrugDrug ResistanceHuman RetrovirusClinical Epidemiology +15

Week 96 efficacy and safety of rilpivirine in treatment-naive, HIV-1 patients in two Phase III randomized trials

Calvin Cohen, Jean‐Michel Molina, Isabel Cassetti, +11

AIDS